Abbott Laboratories $ABT Stock Holdings Lowered by CENTRAL TRUST Co

CENTRAL TRUST Co reduced its stake in Abbott Laboratories (NYSE:ABT) by 10.2% in Q4 2026. Despite this, insiders have been net buyers of the stock, and analysts maintain a “Moderate Buy” rating with an average target price of $119.43. Abbott Laboratories also reported strong quarterly earnings, provided positive FY2026 EPS guidance, and announced a $0.63 quarterly dividend.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin